MYOVANT SCIENCES LTD. Inactive Instrument
Myovant Sciences Ltd.
Equities
MYOV
BMG637AM1024
Biotechnology & Medical Research
Presenter SpeechEric Joseph (Analysts)Okay. Good afternoon, and thanks again for joining the 4...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Myovant Sciences Ltd is a biopharmaceutical company. The Company is focused on redefining care for women and for men through science, medicines and transformative advocacy. The Company's two products include ORGOVYX (relugolix 120 mg), an oral gonadotropin-releasing hormone (GnRH) receptor antagonist for the treatment of adult patients with advanced prostate cancer; and MYFEMBREE, a once-daily oral treatment for the management of heavy menstrual bleeding associated with uterine fibroids. The Company, through its subsidiary, Myovant Sciences GmbH develops supplemental New Drug Application for once-daily MYFEMBREE for the management of moderate to severe pain associated with endometriosis and being assessed for contraceptive efficacy in women ages 18-35 years who are at risk for pregnancy. It develops Relugolix for the treatment of men with advanced prostate cancer. The Company is also developing MVT-602, which has completed a Phase IIa study for the treatment of female infertility.
| 1st Jan change | Capi. | |
|---|---|---|
| +1.80% | 42.59B | |
| +8.52% | 40.65B | |
| +49.22% | 40.57B | |
| -12.36% | 26.77B | |
| +9.00% | 24.81B | |
| -24.35% | 18.17B | |
| +28.93% | 12.05B | |
| -2.62% | 11.7B | |
| +7.14% | 11.1B |
